A detailed history of Envestnet Asset Management Inc transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Envestnet Asset Management Inc holds 220,110 shares of RXRX stock, worth $1.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
220,110
Previous 144,136 52.71%
Holding current value
$1.36 Million
Previous $1.08 Million 34.14%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$5.92 - $8.6 $449,766 - $653,376
75,974 Added 52.71%
220,110 $1.45 Million
Q2 2024

Aug 08, 2024

BUY
$7.35 - $10.05 $75,087 - $102,670
10,216 Added 7.63%
144,136 $1.08 Million
Q1 2024

May 13, 2024

BUY
$9.13 - $15.52 $59,162 - $100,569
6,480 Added 5.08%
133,920 $1.34 Million
Q4 2023

Feb 13, 2024

BUY
$5.09 - $10.79 $648,669 - $1.38 Million
127,440 New
127,440 $1.26 Million

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.12B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Envestnet Asset Management Inc Portfolio

Follow Envestnet Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Asset Management Inc with notifications on news.